VAXART INC by Vaxart, Inc. Analyst Price Targets

Wall Street analyst price targets and consensus rating for VAXART INC by Vaxart, Inc. (VXRT).

Price Target Range — 3 Quarters

Analyst Consensus — 2 Analysts

2Buy

Consensus RatingOutperform# Analysts2Avg. Consensus PT$3Upside to Avg. PT+650.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Mar 27, 2025	B. Riley Securities	Mayank Mamtani	PT Cut	Buy	$3→$2
Aug 15, 2024	Oppenheimer	Cheng Li	Initiate	Outperform	$4
Jan 31, 2024	B. Riley Securities	Mayank Mamtani	Upgrade	Neutral→Buy	$2

Analyst Ratings News

PRO
B. Riley Securities Maintains Buy on Vaxart, Lowers Price Target to $2

B. Riley Securities analyst Mayank Mamtani maintains Vaxart (NASDAQ:VXRT) with a Buy and lowers the price target from $2.5 to $2.

Benzinga Newsdesk

Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside

Oppenheimer initiates Vaxart coverage with an Outperform rating and $4 price target, citing a bullish outlook on its oral vaccines for COVID-19 and norovirus.

Vandana Singh

PRO
Oppenheimer Initiates Coverage On Vaxart with Outperform Rating, Announces Price Target of $4

Oppenheimer initiates coverage on Vaxart (NASDAQ:VXRT) with a Outperform rating and announces Price Target of $4.

Benzinga Newsdesk

PRO
B. Riley Securities Upgrades Vaxart to Buy, Announces $2 Price Target

B. Riley Securities analyst Mayank Mamtani upgrades Vaxart (NASDAQ:VXRT) from Neutral to Buy and announces $2 price target.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on Vaxart, Maintains $4 Price Target

Cantor Fitzgerald analyst Charles Duncan reiterates Vaxart (NASDAQ:VXRT) with a Overweight and maintains $4 price target.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Maintains Overweight on Vaxart, Lowers Price Target to $4

Cantor Fitzgerald analyst Charles Duncan maintains Vaxart (NASDAQ:VXRT) with a Overweight and lowers the price target from $6 to $4.

Benzinga Newsdesk

VAXART INC by Vaxart, Inc.

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

VAXART INC by Vaxart, Inc. Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
B. Riley Securities Maintains Buy on Vaxart, Lowers Price Target to $2

Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside

PRO
Oppenheimer Initiates Coverage On Vaxart with Outperform Rating, Announces Price Target of $4

PRO
B. Riley Securities Upgrades Vaxart to Buy, Announces $2 Price Target

PRO
Cantor Fitzgerald Reiterates Overweight on Vaxart, Maintains $4 Price Target

PRO
Cantor Fitzgerald Maintains Overweight on Vaxart, Lowers Price Target to $4

VAXART INC by Vaxart, Inc.

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

VAXART INC by Vaxart, Inc. Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROB. Riley Securities Maintains Buy on Vaxart, Lowers Price Target to $2

Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside

PROOppenheimer Initiates Coverage On Vaxart with Outperform Rating, Announces Price Target of $4

PROB. Riley Securities Upgrades Vaxart to Buy, Announces $2 Price Target

PROCantor Fitzgerald Reiterates Overweight on Vaxart, Maintains $4 Price Target

PROCantor Fitzgerald Maintains Overweight on Vaxart, Lowers Price Target to $4

PRO
B. Riley Securities Maintains Buy on Vaxart, Lowers Price Target to $2

PRO
Oppenheimer Initiates Coverage On Vaxart with Outperform Rating, Announces Price Target of $4

PRO
B. Riley Securities Upgrades Vaxart to Buy, Announces $2 Price Target

PRO
Cantor Fitzgerald Reiterates Overweight on Vaxart, Maintains $4 Price Target

PRO
Cantor Fitzgerald Maintains Overweight on Vaxart, Lowers Price Target to $4